Product Description
Prometheus has selected a clinical candidate for PR600, targeting an undisclosed member of the tumor-necrosis factor superfamily for the treatment of IBD and is initiating IND-enabling studies. "Partnering with Dr. Falk on PR600 has enabled us to accelerate the PR600 program by sharing costs, resources, and drug development know-how, which has resulted in the achievement of this important milestone within the first year of our collaboration," said Mark McKenna, President and CEO of Prometheus. "We expect to file an Investigational New Drug Application for PR600 in the third quarter of 2022 and plan to explore its utility in other immune-mediated indications beyond IBD." (Sourced from: https://ir.prometheusbiosciences.com/news-releases/news-release-details/prometheus-biosciences-achieves-milestone-payment-dr-falk-pharma)
Mechanisms of Action: TNF Antagonist
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: Eastern America
Company CEO: Robert M. Davis
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Colitis, Ulcerative|Crohn Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
07/18/2022 |
News Article |
Prometheus Biosciences to Host a Virtual R&D Day for Analysts and Investors on July 26, 2022 |
|
03/30/2022 |
News Article |
Prometheus Biosciences Initiates Third Phase 2 Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) |
|
03/28/2022 |
News Article |
Thick Film Devices Market Inclinations & Development Status Highlighted During Forecast Period 2022-2031 |
|
01/03/2022 |
News Article |
Prometheus Biosciences and Dr. Falk Pharma Advance PR600 and Trigger Final Preclinical Milestone Payment |